The development of targeted nanomedicines for cancer therapy has been an utmost focus of
research across different fields including materials science, nanotechnology, biotechnology …

Small interfering RNAs (siRNAs) acting via RNA interference mechanisms are able to
recognize a homologous mRNA sequence in the cell and induce its degradation. The main …

Effective and safe delivery of anticancer agents is among the major challenges in cancer
therapy. The majority of anticancer agents are toxic to normal cells, have poor bioavailability …

Metabolic reprogramming is a hallmark of cancer. Herein we discover that the key glycolytic
enzyme pyruvate kinase M2 isoform (PKM2), but not the related isoform PKM1, is methylated …

Therapeutic efficacy against cancer relies heavily on the ability of the therapeutic agents to
reach their final targets. The optimal targets of most cancer therapeutic agents are usually …

Hyperbranched polymers (HBPs), as a subclass of dendrimers, have attracted the interest of
polymer technologists and scientists around the world. These structures have special …

Nano-drug delivery strategies have been highlighted in cancer treatment, and much effort
has been made in the optimization of bioavailability, biocompatibility, pharmacokinetics …

Breast cancer is the most common malignant disease in women worldwide, but the current
drug therapy is far from optimal as indicated by the high death rate of breast cancer patients …

Hyperbranched polymers (HBPs) have found use in a wide range of applications, such as
optical, electronic and magnetic materials, coatings, additives, supramolecular chemistry …

Barriers to therapeutic transport in biological systems can prevent accumulation of drugs at
the intended site, thus limiting the therapeutic effect against various diseases. Advances in …